Scotiabank Initiates Coverage on Perspective Therapeutics (NYSE:CATX)

Investment analysts at Scotiabank started coverage on shares of Perspective Therapeutics (NYSE:CATX - Get Free Report) in a report issued on Friday, Marketbeat Ratings reports. The firm set a "sector outperform" rating and a $15.00 price target on the stock. Scotiabank's price target suggests a potential upside of 474.71% from the stock's previous close.

Other equities research analysts also recently issued reports about the stock. Wedbush reiterated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Friday, January 24th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday. Oppenheimer decreased their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a research note on Friday, November 22nd. Bank of America downgraded shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Perspective Therapeutics has a consensus rating of "Buy" and a consensus price target of $15.13.

Remove Ads

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded down $0.09 during trading on Friday, reaching $2.61. The company had a trading volume of 466,490 shares, compared to its average volume of 843,163. Perspective Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.05. The stock's 50 day moving average price is $3.21 and its two-hundred day moving average price is $7.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Perspective Therapeutics by 19.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company's stock valued at $224,000 after purchasing an additional 11,472 shares during the period. Velan Capital Investment Management LP acquired a new stake in Perspective Therapeutics in the fourth quarter valued at $1,595,000. Squarepoint Ops LLC acquired a new stake in Perspective Therapeutics in the fourth quarter valued at $626,000. Wexford Capital LP acquired a new stake in Perspective Therapeutics in the fourth quarter valued at $64,000. Finally, Two Sigma Advisers LP acquired a new stake in Perspective Therapeutics in the fourth quarter valued at $484,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.